Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by BearDownAZon Jul 29, 2016 6:46pm
108 Views
Post# 25097453

RE:RE:RE:RE:RE:RE:A checklist of concerns for management

RE:RE:RE:RE:RE:RE:A checklist of concerns for managementSanFran, Toniv and others,

I interpreted the response from Clayton Paradis in a more positive light. First of all, he responded to Kelsee and I within about an hour of sending the initial email a little after 5 PM EST. Second, he didn't brush us off. He only indicated that replying to a select few individuals over email with material information is not allowed and instead any material information released would be disseminated via a public communication. I will re-copy Clayton's statement:
 
"To the extent the company has a material development, the company will update all stakeholders with a broadly disseminated news release.
 
I would point out that many of the noted concerns below would be considered “material” information by the securities regulators and therefore we cannot comment on them here.
 
To the extent the company is able at the time, we will do our best to address these concerns in future public communications."
 
At the end of our letter, we asked "...we would appreciate having [our concerns] addressed in upcoming webcasts, news releases, blog updates, quarterlies, or any other form of media you choose to go with. "
 
We never asked for an email response. Let's be content right now that the message has been received and is being digested. The hope is that come the next quarterly update or AGM that these will be addressed. The only item that I think we should hammer them on is the improvement of the AGM meeting:
 
"2. Improve the Annual General Meeting (AGM): For future AGMs, including the upcoming October 5, 2016 AGM, change the AGM into a "shareholder summit" by webcasting the AGM, giving shareholders (both in Calgary and on the Webcast) ample time to ask questions and preparing more than a cursory presentation that mirrors everything we've seen before and repeatedly."

Let's let them chew on our list for a bit and then we can bug them about this item again if we don't hear back.

Have a great weekend.
BearDownAZ
 
Bullboard Posts